There are 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index and here is how its constituents performed this week, and during the month of September, in descending order, :

1. Seelos (SEEL): No Change this week; UP 22.6% in September
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
2. Allied Corp. (ALID): DOWN 19.6% this week; UP 4.7% in September
   • Has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder.
3. Atai (ATAI): UP 2.8% this week; DOWN 24.1% in September
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
4. GH Research (GHRS): UP 3.8% this week; DOWN 26.9% in September
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
5. Zynerba (ZYNE): DOWN 16.1% this week; DOWN 34.8% in September
   • Is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery.
6. Compass Pathways (CMPS): DOWN 9.1% this week; DOWN 36.0% in September
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
7. Cybin (CYBN): DOWN 12.7% this week; DOWN 54.7% in September
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
8. Mind Medicine (MNMD): DOWN 39.0% this week; DOWN 69.5% in September
   • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
   • Underwent a 1-for-15 reverse stock exchange on August 29th.

In total, the munKNEE Psychedelic Compounds-Based Drug Stock Index went DOWN 8.9% this week (DOWN 15.9% the week before that), DOWN 39.0% in September and is now DOWN 60.8% YTD.

Six other psychedelic companies are primarily focused on the development, expansion and operation of ketamine-assisted therapy (KAT) clinics to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction and substance abuse withdrawal, and depression. They are identified below with a description of each of their commercialization developments:

1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF)
   • Is concentrating on the treatment of Alcohol Use Disorder (AUM)
     • has 3 KAT clinics, 2 in the U.K. and 1 in Norway and
     • is developing MDMA-assisted therapy for AUM
   •  Is also in the process of developing KAT for Gambling Disorder
   • Go here for the company's latest quarterly (Q2) financial results.
2. Delic Corp. (CSE: DELC|OTCQB: DELCF)
   • Has 13 ketamine-assisted therapy (KAT) clinics in the U.S.
3. Field Trip Health and Wellness Ltd.  (TSXV:FTHW|OTCQB:  FTHWF)
   • Is concentrating on therapies for the treatment of resistant depression, post-traumatic stress disorder and disorders affecting the central nervous systems;
   • Operates KAT clinics in Canada (3), the U.S. (8) and Europe (1)
4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF)
   • has 3 KAT clinics in Canada;
   • has the ability to undertake treatments using psilocybin and MDMA in Canada as authorized by Health Canada's Special Access Program;
   • Has 6 KAT clinics in Utah and 2 in Arizona
5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB:  RVLWF)
   • Has 10 KAT clinics in 6 states and 9 options on other clinics
6. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)
   • Is concentrating on the treatment of Opioid Use Disorder using ibogaine which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the US) facilitating research and development toward medicalization

The  above psychedelic-assisted therapy clinic stocks were unchanged, on average, this week (DOWN 13.7% the week before that) and went DOWN 24.1% in September.

More By This Author:

Canada's Major Marijuana LPs Continued To Decline In September
Amended Jushi Holdings Q2 Financials Show Considerable Improvement
These Cryptocurrency ETFs Continue To Dramatically Outperform Bitcoin & Ethereum